MMP inhibition as a potential therapeutic strategy for CHF

M. Lindsey, R. T. Lee

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Congestive heart failure (CHF) is a leading cause of death in developed countries and its prevalence is increasing throughout the world. Progressive left ventricular dilation and contractile dysfunction cause most cases of CHF. Recent therapies have targeted the neurohumoral system, with few therapies directed toward the actual dilation process; however, emerging data indicate that certain members of the family of metalloenzymes, the matrix metalloproteinases, are not only associated with ventricular dilation, but may actually mediate the dilation process. Because these enzymes are extracellular and are pharmacologic targets, matrix metalloproteinase inhibition is a novel potential therapy for delaying or preventing heart failure. (C) 2000 Prous Science.

Original languageEnglish (US)
Pages (from-to)350-354
Number of pages5
JournalDrug News and Perspectives
Volume13
Issue number6
StatePublished - Nov 28 2000

Fingerprint

Matrix Metalloproteinases
Dilatation
Heart Failure
Therapeutics
Developed Countries
Cause of Death
Inhibition (Psychology)
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

MMP inhibition as a potential therapeutic strategy for CHF. / Lindsey, M.; Lee, R. T.

In: Drug News and Perspectives, Vol. 13, No. 6, 28.11.2000, p. 350-354.

Research output: Contribution to journalReview article

@article{a606fc2b0b414f7f9019590acc252086,
title = "MMP inhibition as a potential therapeutic strategy for CHF",
abstract = "Congestive heart failure (CHF) is a leading cause of death in developed countries and its prevalence is increasing throughout the world. Progressive left ventricular dilation and contractile dysfunction cause most cases of CHF. Recent therapies have targeted the neurohumoral system, with few therapies directed toward the actual dilation process; however, emerging data indicate that certain members of the family of metalloenzymes, the matrix metalloproteinases, are not only associated with ventricular dilation, but may actually mediate the dilation process. Because these enzymes are extracellular and are pharmacologic targets, matrix metalloproteinase inhibition is a novel potential therapy for delaying or preventing heart failure. (C) 2000 Prous Science.",
author = "M. Lindsey and Lee, {R. T.}",
year = "2000",
month = "11",
day = "28",
language = "English (US)",
volume = "13",
pages = "350--354",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "6",

}

TY - JOUR

T1 - MMP inhibition as a potential therapeutic strategy for CHF

AU - Lindsey, M.

AU - Lee, R. T.

PY - 2000/11/28

Y1 - 2000/11/28

N2 - Congestive heart failure (CHF) is a leading cause of death in developed countries and its prevalence is increasing throughout the world. Progressive left ventricular dilation and contractile dysfunction cause most cases of CHF. Recent therapies have targeted the neurohumoral system, with few therapies directed toward the actual dilation process; however, emerging data indicate that certain members of the family of metalloenzymes, the matrix metalloproteinases, are not only associated with ventricular dilation, but may actually mediate the dilation process. Because these enzymes are extracellular and are pharmacologic targets, matrix metalloproteinase inhibition is a novel potential therapy for delaying or preventing heart failure. (C) 2000 Prous Science.

AB - Congestive heart failure (CHF) is a leading cause of death in developed countries and its prevalence is increasing throughout the world. Progressive left ventricular dilation and contractile dysfunction cause most cases of CHF. Recent therapies have targeted the neurohumoral system, with few therapies directed toward the actual dilation process; however, emerging data indicate that certain members of the family of metalloenzymes, the matrix metalloproteinases, are not only associated with ventricular dilation, but may actually mediate the dilation process. Because these enzymes are extracellular and are pharmacologic targets, matrix metalloproteinase inhibition is a novel potential therapy for delaying or preventing heart failure. (C) 2000 Prous Science.

UR - http://www.scopus.com/inward/record.url?scp=0033748050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033748050&partnerID=8YFLogxK

M3 - Review article

C2 - 12937656

AN - SCOPUS:0033748050

VL - 13

SP - 350

EP - 354

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 6

ER -